The market for transfection reagents and equipment is projected to expand from US$ 1,170.79 million in 2022 to US$ 2,145.03 million by 2030, reflecting a compound annual growth rate (CAGR) of 7.8% during the period from 2022 to 2030.

The increasing economic impact of cancer is a significant factor propelling the growth of the transfection reagents and equipment market.

As reported by the World Health Organization (WHO), cancer remains one of the foremost causes of mortality globally, resulting in approximately 10 million deaths in 2020. The International Agency for Research on Cancer forecasts that the global cancer incidence will rise, with an additional 30.2 million cases expected by 2040. The Breast Cancer Organization notes that around 5-10% of breast cancer cases are hereditary, stemming from genetic mutations passed through generations. A study titled "Lifestyle, Genetic Risk and Incidence of Cancer," published in the International Journal of Epidemiology in 2023, indicates that nearly one-third of cancer cases are hereditary, highlighting the significant role of genetic mutations in cancer development. Consequently, many individuals are opting for genetic profiling to facilitate early detection and personalized treatment strategies for hereditary cancers. Genes such as BRCA1 and BRCA2, known as tumor suppressor genes, are linked to increased risks of various cancers, particularly breast and ovarian cancers. Individuals inheriting harmful variants of these genes often develop cancer at younger ages compared to those without such mutations. Research into how cancer cells process nucleic acids is expected to enhance our understanding of cancer metabolism. Typically, DNA is encapsulated within viral or non-viral particles for cellular transfection. Gene transfer has emerged as a promising strategy to improve the efficacy of antitumor medications in treating challenging or metastatic cancers. The combination of gene therapy with traditional drugs has been shown to amplify the antiproliferative effects of standard treatments for various cancers, including lung, colorectal, pancreatic, bladder, and breast cancers. Therefore, the rising economic burden of cancer significantly supports the growth of the transfection reagents and equipment market.

The manufacturing of cell and gene therapies is a complex endeavor, necessitating meticulous execution and oversight. Advances in biotechnology have paved the way for personalized treatment options for a range of conditions. Cell and gene therapies are predominantly utilized for chronic illnesses such as neurological disorders, cancer, and genetic diseases. The primary benefits of these therapies include targeted treatment, expedited recovery, and minimized side effects. The global adoption of cell and gene therapies is bolstered by the availability of products approved by the Food and Drug Administration (FDA). For example, in 2022, the FDA approved ADSTILADRIN, an adenovirus developed by Ferring Pharmaceuticals A/S, which delivers human interferon alfa-2b cDNA to the bladder epithelium for treating specific bladder cancer types. Additionally, CARVYKTI, produced by Janssen Biotech, Inc., received FDA approval in 2022. This autologous CAR-T cell therapy, engineered with lentivirus, targets BCMA-expressing tumor cells to treat certain relapsed or refractory multiple myeloma cases.

A 2020 article from University College London (UCL) titled "Gene therapy process change evaluation framework: Transient transfection and stable producer cell line comparison" reported that 423 clinical trials were underway to evaluate gene therapy products. Currently, scientists utilize transfection techniques in the development of these therapies. Thus, the growing interest in cell and gene therapy initiatives is driving an increase in transfection procedures, which in turn propels the growth of the transfection reagents and equipment market.

The transfection reagents and equipment market is categorized by product, modality, application, end user, and region. In terms of product, the market is divided into reagents and equipment. By modality, it encompasses viral, non-viral, and hybrid methods. The applications of transfection reagents and equipment include biomedical research, protein production, and therapeutic delivery. The end-user classification includes academic and research institutions as well as pharmaceutical and biotechnological companies.

Geographically, the market is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America currently leads the global transfection reagents and equipment market, while the Asia Pacific region is anticipated to exhibit the highest CAGR from 2022 to 2030. Cell and gene therapies (CGTs) are increasingly prescribed for patients with severe and rare diseases that lack effective treatments. The manufacturing of CGTs is intricate, with inadequate infrastructure and expertise posing significant challenges. Logistics issues related to intermediates and final products further restrict the manufacturing capacity for CGTs. The CGT production process involves extracting autologous cells through apheresis, transporting them to specialized labs, and returning them to clinics for patient administration, all under stringent quality control measures. To date, the FDA has approved only seven CGT drugs, while approximately 1,200 experimental therapies are in the pipeline, with half of these in Phase 2 clinical trials. Given these developments, annual sales of cell and gene therapies are projected to grow by 15% and around 30%, respectively, according to the Chemical & Engineering News Report 2023. Many manufacturers are collaborating with contract development manufacturing organizations (CDMOs) like Labcorp, Lonza, and Catalent to navigate the challenges associated with the production and commercialization of their CGT products. Lonza has invested approximately US$ 9.2 million to enhance its capabilities in cell and gene therapy manufacturing. Such initiatives by CDMOs are significantly contributing to the expansion of the transfection reagents and equipment market in the United States.

Key primary and secondary sources utilized in the preparation of the report on the transfection reagents and equipment market include ClinicalTrails.com, the Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO), and the Food and Drug Administration (FDA).